139 related articles for article (PubMed ID: 9300812)
1. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.
Björquist P; Ehnebom J; Inghardt T; Deinum J
Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812
[TBL] [Abstract][Full Text] [Related]
2. Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1.
Björquist P; Ehnebom J; Deinum J
Biochim Biophys Acta; 1999 Apr; 1431(1):24-9. PubMed ID: 10209275
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator.
Björquist P; Brohlin M; Ehnebom J; Ericsson M; Kristiansen C; Pohl G; Deinum J
Biochim Biophys Acta; 1994 Dec; 1209(2):191-202. PubMed ID: 7811690
[TBL] [Abstract][Full Text] [Related]
4. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
5. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.
Debrock S; Declerck PJ
FEBS Lett; 1995 Dec; 376(3):243-6. PubMed ID: 7498551
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies against human tissue plasminogen activator (tPA): quantitation of free tPA in human cell cultures by an ELISA.
Kurokawa T; Toyoda Y; Iwasa S
J Biochem; 1991 Feb; 109(2):217-22. PubMed ID: 1713912
[TBL] [Abstract][Full Text] [Related]
8. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
10. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
Debrock S; Declerck PJ
Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
[TBL] [Abstract][Full Text] [Related]
11. Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand.
Cheng XF; Bäck O; Nilsson TK; Nylander Lundqvist E; Pohl G; Wallén P
Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):407-13. PubMed ID: 1332673
[TBL] [Abstract][Full Text] [Related]
12. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
[TBL] [Abstract][Full Text] [Related]
13. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody that does not recognize tissue-type plasminogen activator bound to its naturally occurring inhibitor.
Schleef RR; Wagner NV; Sinha M; Loskutoff DJ
Thromb Haemost; 1986 Dec; 56(3):328-32. PubMed ID: 2436333
[TBL] [Abstract][Full Text] [Related]
15. Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.
Muehlenweg B; Guthaus E; de Prada NA; Schmitt M; Schmiedeberg N; Kotzsch M; Creutzburg S; Kramer MD; Kessler H; Wilhelm OG; Magdolen V
Thromb Res; 2000 Apr; 98(1):73-81. PubMed ID: 10706935
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
Kvassman JO; Verhamme I; Shore JD
Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
[TBL] [Abstract][Full Text] [Related]
17. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
[TBL] [Abstract][Full Text] [Related]
18. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
[TBL] [Abstract][Full Text] [Related]
20. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
